JP2017533945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533945A5 JP2017533945A5 JP2017526516A JP2017526516A JP2017533945A5 JP 2017533945 A5 JP2017533945 A5 JP 2017533945A5 JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017533945 A5 JP2017533945 A5 JP 2017533945A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- combination
- sulbactam
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 208000035143 Bacterial infection Diseases 0.000 claims 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims 7
- 239000003781 beta lactamase inhibitor Substances 0.000 claims 7
- 229940126813 beta-lactamase inhibitor Drugs 0.000 claims 7
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 claims 6
- 229960005256 sulbactam Drugs 0.000 claims 6
- 244000052769 pathogen Species 0.000 claims 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 3
- 229960000723 ampicillin Drugs 0.000 claims 3
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims 3
- 229960004682 cefoperazone Drugs 0.000 claims 3
- 159000000000 sodium salts Chemical class 0.000 claims 3
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 claims 3
- 241000589291 Acinetobacter Species 0.000 claims 2
- 241001453380 Burkholderia Species 0.000 claims 2
- 241000588921 Enterobacteriaceae Species 0.000 claims 2
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims 2
- DHSUYTOATWAVLW-WFVMDLQDSA-N cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 claims 2
- 229960004912 cilastatin Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 2
- 229960002182 imipenem Drugs 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080667P | 2014-11-17 | 2014-11-17 | |
| US62/080,667 | 2014-11-17 | ||
| PCT/US2015/061076 WO2016081452A1 (en) | 2014-11-17 | 2015-11-17 | Combination therapy for treatment of resistant bacterial infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533945A JP2017533945A (ja) | 2017-11-16 |
| JP2017533945A5 true JP2017533945A5 (https=) | 2018-12-20 |
| JP6764862B2 JP6764862B2 (ja) | 2020-10-07 |
Family
ID=54704148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526516A Active JP6764862B2 (ja) | 2014-11-17 | 2015-11-17 | 耐性細菌感染症の治療のための併用療法 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9968593B2 (https=) |
| EP (1) | EP3221313B1 (https=) |
| JP (1) | JP6764862B2 (https=) |
| KR (1) | KR102542392B1 (https=) |
| CN (1) | CN107108624B (https=) |
| AU (1) | AU2015350128B2 (https=) |
| BR (1) | BR112017010132B1 (https=) |
| CA (1) | CA2966632C (https=) |
| CY (1) | CY1121384T1 (https=) |
| DK (1) | DK3221313T3 (https=) |
| EA (1) | EA033829B1 (https=) |
| ES (1) | ES2717776T3 (https=) |
| HK (1) | HK1244798B (https=) |
| HR (1) | HRP20190580T1 (https=) |
| HU (1) | HUE044061T2 (https=) |
| IL (1) | IL251979B (https=) |
| LT (1) | LT3221313T (https=) |
| ME (1) | ME03357B (https=) |
| MX (1) | MX2017006383A (https=) |
| MY (1) | MY196240A (https=) |
| PH (1) | PH12017500852B1 (https=) |
| PL (1) | PL3221313T3 (https=) |
| PT (1) | PT3221313T (https=) |
| RS (1) | RS58429B1 (https=) |
| SG (1) | SG11201703633TA (https=) |
| SI (1) | SI3221313T1 (https=) |
| SM (1) | SMT201900187T1 (https=) |
| TR (1) | TR201905233T4 (https=) |
| TW (1) | TWI690317B (https=) |
| WO (1) | WO2016081452A1 (https=) |
| ZA (1) | ZA201703245B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102542392B1 (ko) | 2014-11-17 | 2023-06-09 | 엔타시스 테라퓨틱스 리미티드 | 내성 박테리아 감염의 치료를 위한 배합물 치료제 |
| WO2017203266A1 (en) * | 2016-05-25 | 2017-11-30 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
| CN114591223B (zh) * | 2016-09-16 | 2025-01-24 | 恩塔西斯治疗有限公司 | β-内酰胺酶抑制剂化合物 |
| EP3301094A1 (en) * | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| EA037916B1 (ru) * | 2017-02-08 | 2021-06-07 | Энтасис Терапеутикс Лимитед | Соединения-ингибиторы бета-лактамаз |
| NZ758200A (en) | 2017-05-08 | 2025-12-19 | Entasis Therapeutics Inc | Compounds and methods for treating bacterial infections |
| CN109422765B (zh) * | 2017-09-05 | 2020-08-28 | 香港理工大学深圳研究院 | C类β-内酰胺酶抑制剂及其制备方法和应用 |
| ES2953362T3 (es) * | 2018-03-13 | 2023-11-10 | Sepsia Therapeutics S L | Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados |
| CN121154634A (zh) * | 2018-03-14 | 2025-12-19 | 正大天晴药业集团股份有限公司 | 含阿维巴坦的抗菌组合物及其用途 |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| SG11202101255UA (en) | 2018-08-09 | 2021-03-30 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| CN111658642A (zh) * | 2019-03-05 | 2020-09-15 | 广州新创忆药物临床研究有限公司 | 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物 |
| TWI715397B (zh) * | 2019-12-31 | 2021-01-01 | 高雄榮民總醫院 | 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體 |
| EP4125905B1 (en) * | 2020-04-02 | 2024-12-25 | GlaxoSmithKline Intellectual Property Development Limited | Regimen for treating a neisseria gonorrhoeae infection with gepotidacin |
| CA3205756A1 (en) * | 2021-01-20 | 2022-07-28 | Entasis Therapeutics Limited | Fixed dosage antibiotic compositions |
| WO2023206580A1 (en) * | 2022-04-29 | 2023-11-02 | Entasis Therapeutics Limited | Durlobactam crystalline forms |
| WO2025239896A1 (en) * | 2024-05-16 | 2025-11-20 | Entasis Therapeutics, Inc. | Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of acinetobacter baumannii-calcoaceticus complex |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT74682A (en) | 1993-12-29 | 1997-01-28 | Pfizer | Diazabicyclic neurokinin antagonists and pharmaceutical compositions containing them |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) * | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) * | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2848210B1 (fr) * | 2002-12-06 | 2007-10-19 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| FR2914923B1 (fr) | 2007-04-12 | 2013-06-14 | Novexel | Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens. |
| ES2533826T3 (es) * | 2008-01-18 | 2015-04-15 | Merck Sharp & Dohme Corp. | Inhibidores de beta-lactamasa |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| EP2921559A1 (en) | 2008-06-19 | 2015-09-23 | Astra Zeneca Holding France | Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| FR2937034B1 (fr) | 2008-10-10 | 2012-11-23 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens |
| FR2936951B1 (fr) * | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| US9744160B2 (en) | 2011-07-26 | 2017-08-29 | Wockhardt Limited | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
| EP2768503A1 (en) * | 2011-07-26 | 2014-08-27 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| RU2578370C2 (ru) | 2011-08-27 | 2016-03-27 | Вокхардт Лимитед | Производные 1,6- диазабицикло [3,2,1] октан-7-она и их применение при лечении бактериальных инфекционных болезней |
| MX340533B (es) | 2011-08-30 | 2016-07-13 | Wockhardt Ltd | Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. |
| EP3052497B1 (en) | 2011-09-13 | 2017-06-28 | Wockhardt Limited | Nitrogen containing compounds and their use |
| US8796257B2 (en) | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| EP2814483A2 (en) * | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| KR20150003777A (ko) | 2012-03-30 | 2015-01-09 | 큐비스트 파마슈티컬즈 인코포레이티드 | 이속사졸 β-락타마제 억제제 |
| US8969570B2 (en) | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US8916709B2 (en) | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| TW201343645A (zh) | 2012-03-30 | 2013-11-01 | Cubist Pharm Inc | １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑 |
| AR090539A1 (es) * | 2012-04-02 | 2014-11-19 | Astrazeneca Ab | COMPUESTOS INHIBIDORES DE b LACTAMASA |
| RU2693898C2 (ru) | 2012-05-30 | 2019-07-05 | Мейдзи Сейка Фарма Ко., Лтд. | НОВЫЙ ИНГИБИТОР бета-ЛАКТАМАЗЫ И СПОСОБ ЕГО ПОЛУЧЕНИЯ |
| BR112015003592B1 (pt) | 2012-08-25 | 2020-04-14 | Wockhardt Ltd | derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas |
| WO2014033561A1 (en) * | 2012-09-03 | 2014-03-06 | Wockhardt Limited | Antibacterial compositions |
| WO2014122468A1 (en) * | 2013-02-06 | 2014-08-14 | Astrazeneca Ab | Combination therapy for the treatment of nosocomial pneumonia |
| WO2014141132A1 (en) * | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
| KR102542392B1 (ko) | 2014-11-17 | 2023-06-09 | 엔타시스 테라퓨틱스 리미티드 | 내성 박테리아 감염의 치료를 위한 배합물 치료제 |
-
2015
- 2015-11-17 KR KR1020177016295A patent/KR102542392B1/ko active Active
- 2015-11-17 TW TW104137939A patent/TWI690317B/zh active
- 2015-11-17 JP JP2017526516A patent/JP6764862B2/ja active Active
- 2015-11-17 HK HK18104155.3A patent/HK1244798B/en unknown
- 2015-11-17 PH PH1/2017/500852A patent/PH12017500852B1/en unknown
- 2015-11-17 PL PL15801091T patent/PL3221313T3/pl unknown
- 2015-11-17 MX MX2017006383A patent/MX2017006383A/es active IP Right Grant
- 2015-11-17 ES ES15801091T patent/ES2717776T3/es active Active
- 2015-11-17 WO PCT/US2015/061076 patent/WO2016081452A1/en not_active Ceased
- 2015-11-17 HU HUE15801091A patent/HUE044061T2/hu unknown
- 2015-11-17 RS RS20190328A patent/RS58429B1/sr unknown
- 2015-11-17 SI SI201530648T patent/SI3221313T1/sl unknown
- 2015-11-17 SM SM20190187T patent/SMT201900187T1/it unknown
- 2015-11-17 BR BR112017010132-7A patent/BR112017010132B1/pt active IP Right Grant
- 2015-11-17 AU AU2015350128A patent/AU2015350128B2/en active Active
- 2015-11-17 HR HRP20190580TT patent/HRP20190580T1/hr unknown
- 2015-11-17 TR TR2019/05233T patent/TR201905233T4/tr unknown
- 2015-11-17 EP EP15801091.8A patent/EP3221313B1/en active Active
- 2015-11-17 ME MEP-2019-80A patent/ME03357B/me unknown
- 2015-11-17 US US15/527,091 patent/US9968593B2/en active Active
- 2015-11-17 DK DK15801091.8T patent/DK3221313T3/en active
- 2015-11-17 MY MYPI2017000670A patent/MY196240A/en unknown
- 2015-11-17 SG SG11201703633TA patent/SG11201703633TA/en unknown
- 2015-11-17 CN CN201580062519.5A patent/CN107108624B/zh active Active
- 2015-11-17 CA CA2966632A patent/CA2966632C/en active Active
- 2015-11-17 LT LTEP15801091.8T patent/LT3221313T/lt unknown
- 2015-11-17 PT PT15801091T patent/PT3221313T/pt unknown
- 2015-11-17 EA EA201791069A patent/EA033829B1/ru unknown
-
2017
- 2017-04-27 IL IL251979A patent/IL251979B/en active IP Right Grant
- 2017-05-10 ZA ZA2017/03245A patent/ZA201703245B/en unknown
-
2018
- 2018-04-09 US US15/947,959 patent/US10376499B2/en active Active
-
2019
- 2019-03-18 CY CY20191100315T patent/CY1121384T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533945A5 (https=) | ||
| PH12017500852B1 (en) | Combination therapy for treatment of resistant bacterial infections | |
| WO2018115527A3 (en) | Mers coronavirus vaccine | |
| MX2019009443A (es) | Metodos para tratar la influenza. | |
| NZ616806A (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
| MX2015010190A (es) | Metodos de tratamiento topico para infecciones microbianas. | |
| MY179292A (en) | Monobactam organic compounds for the treatment of bacterial infections | |
| UA107423C2 (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
| EA201991523A1 (ru) | Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам | |
| ZA202002093B (en) | Antibacterial compounds | |
| CL2015002755A1 (es) | Composiciones antibióticas de ceftolozano. | |
| EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
| WO2016086153A3 (en) | Use of hsp90 inhibitors for the treatment of hiv infections and aids | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| RU2017145271A (ru) | Терапевтическое средство для фиброза | |
| SA517381678B1 (ar) | مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي | |
| PH12018500358A1 (en) | Compounds for use in an antibacterial applications | |
| IN2014MU00916A (https=) | ||
| EA201890653A1 (ru) | Композиция с противовирусным эффектом | |
| WO2015165964A8 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| MX2017013433A (es) | Composiciones antibacterianas. | |
| PH12017502432A1 (en) | Compositions and methods for using lamellar bodies for therapeutic purposes | |
| AR110913A1 (es) | Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas | |
| EA201890122A1 (ru) | Применение 2-(5s-метил-2-оксо-4r-фенилпирролидин-1-ил)ацетамида в лечении судорог | |
| MX379489B (es) | Metodos para tratar la osteocondromatosis multiple (mo). |